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Background: Retinoblastoma (RB) is childhood malignant tumors with majority of cases 
affect children under 5 years old. RB is caused by mutation in RB1, a tumor suppressor 
gene which is located on chromosome 13q14. The aim of this study is to detect mutations 
and single nucleotide polymorphisms (SNPs) in N- and C-terminus of RB1 in Malaysian 
children with RB, as well as its association with laterality and staging of this disease. 
 
Methods: Peripheral blood leukocytes were collected from 66 retinoblastoma patients 
and 66 healthy volunteers. Tumor tissue specimen also collected from three available 
patients. The DNA was extracted using commercially available extraction kit. PCR were 
conducted using self-designed primers. The mutational analysis was performed using 
DHPLC and direct sequencing method. 
 
Results: Two nonsense mutations and four SNPs were detected in N-terminus, but none 
in C-terminus. The nonsense mutations; Arg320X and Glu323X were detected in 3 
children with RB. A novel SNP, IVS1-3T>G was identified in this study. There was a 
significant different in allele frequency of IVS4-77G>A between patients and healthy 
control group (p=0.044). There was no significant association between polymorphisms 
with laterality and staging of RB. 
 
 
Discussion and conclusion: Arg320X and Glu323X play as important role in the 
predisposition to RB. SNP IVS4-77G>A also have a potential for genetic defect RB in 
our population. However, a larger sample size is needed for more confirmation. The other 
SNPs have more potential to be used as genetic variant markers for population studies 
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KAJIAN VARIASI GENETIK DALAM TERMINUS N, TERMINUS C DAN 
PROMOTER PADA GEN RB1 DI KALANGAN PESAKIT 
RETINOBLASTOMA DI MALAYSIA 
 
ABSTRAK 
 
Retinoblastoma (RB) adalah sejenis kanser mata yang sering terjadi di kalangan 
kanak-kanak yang berumur lima tahun dan ke bawah dengan kekerapan seorang 
pesakit di kalangan 15,000 hingga 20,000 kelahiran. Retinoblastoma boleh terjadi 
secara keturunan atau sporadik. Kanser mata ini berlaku disebabkan oleh mutasi atau 
perubahan pada gen RB1, sejenis gen penindas tumor. Tujuan kajian ini dilakukan 
adalah untuk mengenalpasti mutasi dalam terminus N, terminus C dan promoter pada 
gen RB1 pesakit retinoblastoma serta kaitannya dengan peringkat dan lateraliti 
penyakit tersebut. Seramai 68 kanak-kanak pesakit RB sporadik daripada Hospital 
Universiti Sains Malaysia (HUSM), Hospital Kuala Lumpur (HKL) dan Pusat 
Perubatan Universiti Malaya (PPUM) dan 68 sukarelawan normal dengan padanan 
etnik dengan kumpulan pesakit telah mengambil bahagian didalam kajian ini. 
Sebanyak 3cc darah telah diambil dari pesakit dan sukarelawan. Sampel tisu tumor 
juga telah diambil daripada empat pesakit RB. Sebanyak 200µl DNA telah diekstrak 
menggunakan kit ekstrak darah komersial. PCR telah dijalankan dengan 
menggunakan primer yang direka sendiri untuk ekson dalam terminus N dan 
terminus C serta kawasan intron sekitarnya, dan promoter pada gen RB1. Nisbah 
kanak-kanak lelaki kepada kanak-kanak perempuan adalah 2:1, di mana 79% adalah 
Melayu, 12% Cina dan 9% India. Leukocoria merupakan tanda klinikal awal pada 
sebahagian besar pesakit dan kebanyakan adalah melibatkan sebelah mata tanpa 
 xvii 
 
kecenderungan terhadap mata kanan atau kiri. Secara purata, umur pesakit ketika 
didiagnosis adalah 23.42 (17.64) bulan. Diagnosis lebih awal [17.68 (18.33) bulan] 
melibatkan pesakit RB yang melibatkan kedua-dua belah mata berbanding dengan 
pesakit sebelah mata [28.65 (15.46) bulan]. Berdasarkan umur ketika diagnosis 
terdapat perbezaan statistik yang ketara (p=0.011) di antara dua kumpulan ini. 
Terdapat juga kaitan yang ketara di antara lateraliti dengan bangsa pesakit RB 
(p=0.025). Dua mutasi tiada makna dan empat polimorfisma nukleotida tunggal 
(SNPs) telah dikenalpasti dalam terminus N; satu SNP telah dikenalpasti dalam 
promoter, tetapi tiada sebarang mutasi mahupun polimorfisma yang dijumpai dalam 
terminus C. Semua mutasi dan polimorfisma yang dijumpai pada 30 pesakit dan 
kawalan melibatkan penggantian nukleotida tunggal yang heterozigus. Mutasi tiada 
makna; Arg320X dan Glu323X telah dikesan pada 3 kanak-kanak RB. Satu nobel 
SNP terbaru, IVS1-3T>G telah ditemui pada seorang pesakit. IVS4-77G>A yang 
telah ditemui pada empat pesakit RB tapi tidak dijumpai pada kumpulan kawalan. 
Polimorfisma ini didapati meningkatkan kecenderungan yang ketara untuk penyakit 
RB (p=0.044). Walaubagaimanapun, tiada kaitan yang ketara ditemui antara semua 
variasi genetik yang ditemui dengan peringkat dan lateraliti pesakit. Tiada perbezaan 
variasi genetik yang dijumpai pada darah dan tisu tumor daripada empat pesakit. 
Bagaimanapun, lebih banyak sampel tisu tumor diperlukan untuk kepastian lebih 
lanjut. Berdasarkan penemuan ini SNP IVS4-77G>A mungkin memainkan peranan 
dalam mempengaruhi risiko seseorang untuk menghidap kanser mata ini. Empat SNP 
yang lain lebih cenderung sebagai penanda variasi genetik dalam populasi. 
Walaubagaimanapun, bilangan sampel yang lebih besar diperlukan bagi tujuan 
pengesahan.  
 xviii 
 
A STUDY OF THE GENETIC VARIATIONS IN N-TERMINUS, C-
TERMINUS AND PROMOTER OF RB1 GENE AMONG 
RETINOBLASTOMA PATIENTS IN MALAYSIA 
 
ABSTRACT 
 
Retinoblastoma (RB) is the most common primary intraocular tumor affecting 
mainly children under five years of age, with a prevalence of 1 in 15 000 to 20 000 
live births. Retinoblastoma is divided into hereditary and sporadic types. It is caused 
by mutations or changes in RB1 gene, a tumor suppressor gene. The aim of this study 
is to detect mutations in N-terminus, C-terminus and promoter region of RB1 gene in 
retinoblastoma patients in Malaysia, as well as its association with staging and 
laterality of the patients. A total of 68 children with sporadic RB from Hospital 
Universiti Sains Malaysia (HUSM), Hospital Kuala Lumpur (HKL) and University 
Malaya Medical Centre (UMMC) and 68 healthy ethnic-matched controls were 
recruited. Venesection was done and 3cc of blood was taken. Tumor tissue samples 
were also collected from four patients. A total of 200µl DNA was extracted using 
commercially available extraction kit. PCR was conducted using self-designed 
primers for exons in N-terminus and C-terminus with its intronic flanking region, and 
promoter region of RB1 gene. Screening for mutations or polymorphisms for N-
terminus was conducted using DHPLC analysis and direct sequence was done for C-
terminus and promoter region. Male to female patient ratio was 2:1, where 79% were 
Malays, 12% Chinese and 9% Indian. Majority of our patients presented with 
leukocoria and unilateral involvement with no predilection to right or left eye. The 
mean age at diagnosis of patients was 23.42 (17.64) months. There was statistical 
 xix 
 
significant difference between age of diagnosis and laterality of the disease 
(p=0.011). Bilateral RB was diagnosed earlier [17.68 (18.33) months) than unilateral 
RB [28.65 (15.46) months). There was also significant association between laterality 
and racial group of RB patients (p=0.025). Two nonsense mutations and four SNPs 
were detected in N-terminus; one SNP was detected in the promoter region. 
However, C-terminus was devoid of any polymorphism or mutation. All mutations 
and polymorphisms which were found in 30 patients and healthy controls involved a 
heterozygous type of single nucleotide substitution. The nonsense mutations; 
Arg320X and Glu323X were detected in 3 children with RB. A novel SNP; IVS1-
3T>G found in this study was identified in one patient. IVS4-77G>A identified in 
four patients was found to significantly increase the susceptibility to develop RB 
(p=0.044). However, there was no significant association between identified 
mutations and polymorphisms with laterality and staging of RB. There was no 
disparity in mutations and polymorphism between peripheral blood leukocytes and 
available tumor tissue. We postulate that SNP IVS4-77G>A might play a role in the 
predisposition to retinoblastoma. The other five SNPs are most likely important as 
genetic variant markers for population studies. However, a larger sample size is 
needed for further confirmation.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 Retinoblastoma 
 
Retinoblastoma (RB) is the most common primary intraocular malignancy of infancy 
and childhood (Abramson and Schefler, 2004). It is a relatively rare form of 
childhood cancer which affects young children under age of 5 years. The tumor 
develops from the immature retina, which is the part of the eye responsible for 
detecting light and color (Figure 1.1). Retinoblastoma was a uniformly fatal disease 
(Albert, 1987). The incidence of RB is estimated to be one in 15,000 and one in 
20,000 live births (Lohmann and Gallie, 2004; Shields and Shields, 2004; Rodriguez 
et al., 2002). Approximately one in three to one in four affected children will have a 
family history of RB. In United States, approximately 300 children are diagnosed 
with retinoblastoma each year (Tamboli et al., 1990). In developed countries, over 
95% of children survive the malignancy by early detection and immediate treatment 
of affected eye (Broaddus et al., 2009b). However, the survival rate can be as low as 
6.8% in less developed countries mainly caused by late presentation and late 
treatment as the tumor extended to the orbit, optic nerve and brain (Shields and 
Shields, 2004). In Malaysia as in most developing countries, parents usually prefer to 
attempt traditional treatment as they afraid of enucleation (Sinniah et al., 1980), and 
only seek modern medical treatment at stage when it is incurable (Menon et al., 
2009). 
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Figure 1.1: Schematic diagram of eye. Retinal cells located at back layer of the 
eye and connected with the optic nerve to transfer the light rays to electrical impulse 
and sent to the brain (http://www.clinicaomegalanzarote.com/en/retina.htm) 
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RB is caused by mutation in RB1 gene, a tumor suppressor gene. RB1 gene is a gene 
which responsible to encode retinoblastoma phosphoprotein (pRB). It is a regulatory 
protein that functions in cell cycle activity. pRB protein normally suppresses the cell 
cycle activity when the cell sends the signal to stop the production of new cells. The 
presence of mutation in RB1 gene is believed to be the main factor leading to loss of 
function of pRB protein in cell cycle activity by altering pRB structure, and initiating 
the tumor development (Knudson, 1971; Lohmann, 1999). 
 
  1.2 Clinical presentation 
 
The clinical presentation of retinoblastoma is dependent on tumor growth pattern, 
duration of disease, degree of tumor vascularity, the presence of calcifications, 
vitreous seeding, and retinal detachment (Kiss et al., 2008). The most common 
presentation of retinoblastoma is leukocoria, an abnormal white discoloration in one 
or both pupils. In United States, almost 60% of all cases of retinoblastoma are 
diagnosed after observation of leukocoria in the affected eye, which initially noticed 
by a parent or relative (Shields et al., 1991). Leukocoria is a white reflection in the 
pupil and only visible at certain angles and under certain light conditions especially 
on flash photography. The survival rate in retinoblastoma patients with leukocoria as 
initial presentation is high (88% at 5 years) but poor prediction for preserving the 
globe (Balmer et al., 2006; Shields and Shields, 2004). The second most common 
sign of retinoblastoma is strabismus, which detected approximately 1 in 5 
retinoblastoma patients in the United States (Abramson et al., 1998). Strabismus, or 
squint, is the impairment of the vision resulting from a loss of central vision in one or 
both eyes. Tumors presenting with strabismus as the initial sign are associated with a 
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higher survival rate (similar to leukocoria), but with a higher chance of preservation 
of the globe (Balmer et al., 2006; Shields and Shields, 2004). The remaining 20% of 
the cases of retinoblastoma present with atypical signs and symptoms, including 
painful red eye, glaucoma, cloudy cornea, vitreous hemorrhage, or signs of orbital 
inflammation mimicking orbital cellulitis (Abramson et al., 1998). These uncommon 
presentations are usually late signs associated with more advanced disease and poor 
salvation of the globe (Balmer et al., 2006; Butros et al., 2002). Some children with 
retinoblastoma may be asymptomatic (Aerts et al., 2006). The presenting signs and 
symptoms in advanced stage usually correlate with the degree of extraocular 
invasion, which can result in orbital swelling and proptosis (Chintagumpala et al., 
2007). 
 
Retinoblastoma growth patterns are subdivided into endophytic and exophytic. 
Endophytic retinoblastoma accounting for nearly 60% of cases, exhibit growth 
toward the vitreous cavity as a result of cell division within the inner retinal layers 
(Palazzi et al., 1990). It can be unifocal or multiple foci, isolated or fused, variable in 
size, round or oval-shaped, and appears as calcified creamy-white mass or 
vascularized pink retinal mass. Endophytic lesion has higher tendency for vitreous 
seeding (Balmer et al., 2006). The location of endophytic retinoblastoma is tumor 
age-dependent. The earliest tumors usually develope closer to the posterior pole and 
later progresses anteriorly (Abramson and Gombos, 1996). Approximately 39% of 
retinoblastoma presented as exophytic growth pattern with tumor development in the 
outer retinal layers and expansion beneath the retina into the subretinal space 
(Palazzi et al., 1990). Retinal detachment is the common presentation in exophytic 
retinoblastoma (Palazzi et al., 1990). Choroidal invasion also occur significantly 
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more often in patients with exophytic retinoblastoma than in those with endophytic 
retinoblastoma (Palazzi et al., 1990). 
 
Retinoblastoma can involve unilateral or bilateral. Unilateral involvement is seen in 
60% of retinoblastoma cases, the disease is unilateral and the median age at 
diagnosis is two years. 15% of unilateral cases are hereditary (Aerts et al., 2006). 
Patients with bilateral tumors have one or more tumors in both eyes. It is presumed 
that these patients have the hereditary form of the disease even in the absence of a 
positive family history. The severity of tumors may be variable in the two eyes, and 
this becomes important in weighing potential treatment options. Retinoblastoma is 
bilateral in about 40% of cases with a median age at diagnosis of one year (Lohmann 
and Gallie, 2004). Trilateral retinoblastoma refers to bilateral retinoblastoma 
associated with an intracranial neuroblastic tumor of the pineal gland called 
pinealoblastoma (Paulino, 1999). Trilateral retinoblastoma was recognized to be the 
most frequent cause of death among children with hereditary RB in the first decade 
of life, accounting for 50% of all deaths (Blach et al., 1994), and occurs in 
approximately 8% of patients with hereditary retinoblastoma (De Potter et al., 1994). 
The median survival time after diagnosis of trilateral retinoblastoma was 9 months 
(Kivela, 1999). 
 
1.2.1 Staging 
 
Retinoblastoma can be classified according to three classifications; Tumor-node-
metastasis (TNM) classification, Reese-Ellsworth (RE) classification, and the new 
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International Classification of Retinoblastoma (ICRB). The classification or staging 
helps to prognosticate the survival, treatment options as well as visual potential. 
 
As retinoblastoma has spread beyond the eye, the TNM classification used to stage 
disease. T describes the size of the tumor and whether it has invaded nearby tissue; N 
describes regional lymph nodes that are involved; M describes distant metastasis. 
Groups T1 and T2 staged the tumor contained in the eye, however, the International 
Intraocular Retinoblastoma Classification (ICRB) and Reese-Ellsworth (RE) 
Classification are globally preferred for staging of retinoblastoma, as they are better 
predictors of treatment outcome. 
 
The Reese-Ellsworth classification was introduced in 1963 following the 
presentation by Reese and Ellsworth during 67th annual meeting of the American 
Academy of Ophthalmology. The classification was based on intraocular tumor 
staging and prediction on globe salvation following external beam radiation (Reese 
and Ellsworth, 1963). External beam radiation was the main treatment during this 
era. It has gained wide popularity for the last four decades. However, the Reese-
Ellsworth classification failed to address the problem of subretinal seeding and did 
not differentiate between focal and diffuse vitreous seeding. For these reasons, the  
Reese–Ellsworth classification was found to be a poor predictor of chemoreduction 
success (Shields and Shields, 2004). Therefore, a new classification for 
retinoblastoma was designed (Linn Murphree, 2005). 
 
The new classification, the International Classification of Retinoblastoma (ICRB) 
(Table 1.1), was developed to predict the outcome from combination chemotherapy 
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and focal therapy. It based mainly on the extent of tumor seeding in the vitreous and 
subretinal space, with consideration for tumor size and location (Linn Murphree, 
2005). ICRB was later accepted as standard staging for intraocular tumor globally in 
the early 2000s. The chances of maintaining useful vision decreased exponentially 
from groups A to E. Each eye is staged independently. 
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Table 1.1: The International Classification of Retinoblastoma 
 
Group Quick reference Specific features 
A Small tumor RB <3 mm* 
B 
Larger tumor 
Macula 
Juxtapapillary 
Subretinal fluid 
RB >3 mm* in size or 
Macular RB location (<3 mm to foveola) 
Juxtapapillary RB location (<1.5 mm to disc) 
Additional subretinal fluid <3 mm from margin 
C Focal seeds 
RB with: 
Subretinal seeds <3 mm from RB 
Vitreous seeds <3 mm from RB 
Both subretinal and vitreous seeds <3 mm from RB 
D Diffuse seeds 
RB with: 
Subretinal fluid >3 mm from RB 
Subretinal seeds > mm from RB 
Vitreous seeds >3 mm from RB 
Both subretinal and vitreous seeds >3 mm from RB 
E Extensive  RB 
Extensive RB occupying >50% globe or 
Neovascular glaucoma 
Opaque media from hemorrhage in anterior 
chamber, vitreous, or subretinal space 
Invasion of postlaminar optic nerve, choroid (>2 
mm), sclera, orbit, anterior chamber 
RB – retinoblastoma 
*refers to 3 mm in basal dimension or thickness 
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1.2.2 Second malignant neoplasm (SMN) 
 
Hereditary retinoblastoma is associated with higher risk of developing second 
malignancies throughout life (Margo et al., 1998). More children with RB die from 
the second malignant neoplasms than from the retinoblastoma itself (Abramson, 
1999). The cumulative incidence of second malignancy in hereditary retinoblastoma 
after 50 years of diagnosis is 51%, 10 times higher compared to 5% in nonhereditary 
cases (Abramson and Frank, 1998; Wong et al., 1997). The mean response time 
between retinoblastoma and second malignancy is approximately 13 years (Wong et 
al., 1997; Margo et al., 1983; Draper et al., 1986). The most common SMNs are 
osteosarcoma (37%), followed by soft-tissue sarcoma (7%) and melanoma (7%) 
(Moll et al., 1997a). Other reported malignancies including neuroblastoma, 
rhabdomyosarcoma, glioma, leukemia, squamous cell carcinoma and cutaneous 
melanoma (Wong et al., 1997; Margo et al., 1983; Draper et al., 1986). External-
beam radiotherapy plays a major role in pathogenesis of second malignant 
neoplasms, and shows a radiation dose-response relationship for all sarcomas (Wong 
et al., 1997). With longer follow-up of diagnosis of retinoblastoma, the incidence of 
SMN in cases that were treated with external-beam radiotherapy is more than 
doubled when compared with those not receiving radiotherapy (58% and 27% 
respectively) (Abramson and Frank, 1998). 
 
1.3 Knudson two-hit hypothesis 
 
The genetics of retinoblastoma initiated the paradigm of understanding a genetically 
inherited cancer and provides the basis for the two-hit hypothesis of carcinogenesis 
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(Friedman et al., 2000). Deletion, mutation, inactivation or total loss of both copies 
of the RB1 gene at the 13q14 locus need to occur in order for retinoblastoma to 
develop (Shields and Shields, 2004). Knudson (1971) proposed the “two hit” 
hypothesis to explain the events that are necessary for both hereditary and non-
hereditary retinoblastoma. He used the knowledge about the time of clinical 
presentation of retinoblastoma and the number of cell divisions in human retina. His 
theory was based on a comparative analysis of unilateral and bilateral retinoblastoma 
cases. Hereditary retinoblastoma occurs when the first mutational event or “hit” is at 
germinal level of retinal cell which is transmitted from the parent, followed by the 
second “hit” which occurs in somatic cell during development. This possibly 
explained the hereditary retinoblastoma; all cells in the body are predisposed to 
possible tumor development inherited from germline mutation (“first hit”). This 
explains the high incidence of second nonocular tumors, such as osteosarcoma. By 
contrast, sporadic or non-hereditary retinoblastoma, the “two hits” occur during 
development of the retina and both “hits” are somatic mutations. The rest of the body 
theoretically carries no higher risk to develop other tumors because these patients 
presumably have normal chromosomal structure elsewhere in the body (Shields and 
Shields, 2004). 
 
1.4 RB1 
 
A tumor suppressor gene is a gene that encodes a protein to inhibit cell division. 
Tumor suppressor gene and their gene products must be inactive or absent for the 
cell to divide. Permanent inactivation through mutation causes the disruption of 
division and induces uncontrolled proliferation of tumor cell. 
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RB1 was the first tumor suppressor gene to be identified which is responsible for 
retinoblastoma (Friend et al., 1986). RB1 is located on the long arm of chromosome 
13 in region 13q14 (Figure 1.2). The genomic locus of RB1 consists of 27 exons 
distributed over 200 kilobases (Wiggs et al., 1988) (Figure 1.3). The sizes of exons 
range from 31 to 1889 base pairs, while the 26 introns span 80 to 71712 base pairs 
(Hong et al., 1989). Promoter region of RB1 is identified at 186 to 206 bp upstream 
from initiation codon. It contains binding domain for various transcription factor 
protein such as RBF-1, Sp1, ATF and E2F (Ohtani-Fujita et al., 1993). The RB1 gene 
transcribed into a 4.7 kb messenger RNA (mRNA), which encodes a 110 kDa 
nuclear phosphoprotein of 928 amino acids. It is known as pRB (Lee et al., 1987). 
pRB acts as a cell-cycle regulated growth suppressor. The absence of pRB has been 
confirmed in retinoblastoma cell lines (Goodrich and Lee, 1993).  
 
It is postulated that the development of cancer occurs when there is mutation of both 
alleles of this tumor suppressor gene. Apart from retinoblastoma, mutations 
involving RB1 gene also predisposes to a variety of other tumors including 
osteosarcoma (Dryja et al., 1986; Toguchida et al., 1988), breast cancer (Eyfjord and 
Thorlacius, 1992; Ceccarelli et al., 1998), acute leukemia (Sauerbrey et al., 1998; 
Kornblau et al., 1998; Ahuja et al., 1991), bladder cancer (Grossman et al., 1998; 
Niehans et al., 1999), lung cancer (Otterson et al., 1994; Harbour et al., 1988) and 
other cancers in later life (Sellers and Kaelin, 1997). 
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Figure 1.2: Location of RB1 gene at q-arm (long arm) of chromosome 13, at sub-
band 14.2 (http://ghr.nlm.nih.gov/dynamicImages/chromomap/RB1.jpeg). 
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1.4.1 pRB 
 
The protein product of RB1 is a nuclear phosphoprotein (pRB) with DNA binding 
properties (Lee et al., 1987). It acts as a cell cycle regulator, which blocks the 
transition of normal cells from G0/G1 into S phase of the cell cycle (Ludlow et al., 
1990). pRB has the ability to bind and inhibit the transcription factor; E2F, that 
activate the genes involved in cell division. E2Fs bind to pRB in the pocket domain 
and the carboxy-terminal region of the protein. Thus, mutations at either of these 
locations could reduce the binding potential to E2F and allows for uncontrolled entry 
into the S-phase and contribute to rapid cell division (Harbour and Dean, 2000). 
 
pRB consist of four domains; N terminus, pocket A and B domain and C terminus 
(Figure 1.3 (c)). Combination of small pocket A and B and part of C terminus make 
a complex which is known as large pocket domain (Harbour, 1998). Pocket domain 
A and B of pRB protein acting as the binding site for other proteins in transcription 
process (Chow and Dean, 1996; Chellappan et al., 1991). Frequent mutations have 
been identified within this region that is associated with non-functioning of pRB 
(Braggio et al., 2004; Lohmann, 1999). N and C termini were less studied, hence 
their function is not clearly known. Some studies found interaction of pRB binding 
protein through this residue (Inoue et al., 1995). A study by Xu et al., (1994) 
suggested that N-terminus of pRB protein may play a role in regulation of cell 
growth or differentiation. The C-terminus is part of large pocket domain, which 
contains some important domains for protein-protein interaction (Shew et al., 1990). 
For example c-Abl tyrosin kinase which might have the potential to regulate the 
transcriptional activity in S-phase of cell cyle (Welch and Wang, 1993). 
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Figure 1.3: Organisation of the RB1 gene and protein, pRB. (a) Genomic 
organisation of the RB1 gene. (b) Organisation of the 27 exons containing the open 
reading frame. (c) Structure of the pRb protein. kb-kilobase pair; bp-base pair; aa-
amino acid. (Modified from http://www.els.net/WileyCDA/ElsArticle/refId-
a0006053.html) 
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1.4.1 (a) N-terminus 
 
The amino-terminal (N-terminus) region of RB1 comprised of exon 1 to exon 11. 
Although the N-terminus is not structurally well defined, yet it is still known to be an 
important essential part of the protein. Deletion mutants of N-terminus have been 
found to cause retinoblastoma in human (DiCiommo et al., 2000). There are 6 
consensus CDK phosphorylation sites in N-terminus, which may play a role in 
regulating pRB in the cell cycle (Knudsen and Wang, 1997). In addition, this region 
contains binding sites for MCM7 (a replication licensing factor), a kinase that 
phosphorylates both pRB and histone H1 in the G2/M phase of the cell cycle and 
other proteins (Sterner et al., 1998). Moreover, mice that have been genetically 
engineered to lack of pRB die before embryonic day 16 with severe developmental 
and apoptotic defects (Lee et al., 1992). However, expression of pRB lacking the N-
terminus region delayed this embryonic mortality, but did not prevent it (Riley et al., 
1997). Similarly, this N-terminus deficient mutant delayed but did not prevent the 
pituitary tumors seen in mice heterozygous for RB1 deletion (Riley et al., 1997). 
These results suggest that the N-terminus region is important but not completely 
essential for pRB function and tumor suppression.  
 
1.4.1 (b) C-terminus 
 
The carboxy-terminal (C-terminus) region of RB1 is composed of exon 22 to exon 
27. This region has non-specific DNA-binding activity (Wang et al., 1990). 
However, C-terminus domain was found to play crucial role for growth suppression 
of retinoblastoma (Qian et al., 1992). In addition, this region was also found to be 
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important for function and regulation of RB1 gene (Durfee et al., 1994). The cyclin 
binding motif of C-terminus that is important for phosphorylation of RB protein 
(Adams et al., 1999).  The C- and N-termini are appear to bind with the pocket 
domain of RB. This domain is important for phosphorylation of the RB1 protein, 
which is a control point for the activation or deactivation of the protein. The C-
terminal region also binds the oncoproteins c-Abl and MDM2 (Whitaker et al., 
1998). Deletion of exons 24 and 25 within the C-terminus of RB1 gene was 
associated with low-penetrance retinoblastoma (Bremner et al., 1997). 
 
1.4.1 (c) Promoter of RB1 
 
Inactivation of the RB1 gene is mostly caused by mutations affecting the coding 
region and promoter region (Shimizu et al., 1994). Bookstein et al., (1990) reported 
an association between prostate cancer and 103-bp deletion of the promoter region 
that abrogated RB promoter activity. In addition to genetic changes such as sequence 
variations or deletions, epigenetic changes such as CpG hypermethylation can 
inactivate a promoter. Ohtani-Fujita et al. (1993) reported 9 unilateral, sporadic 
retinoblastoma cases associated with hypermethylation in the 5' region of the RB1. 
CpG methylation in the RB promoter inhibits binding of the retinoblastoma binding 
factor 1 (RBF-1) and the activating transcription factor (ATF)-like factors, that cause 
reduction in RB promoter activity (Ohtani-Fujita et al., 1993). 
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1.4.2 pRB and cell cycle 
 
In mammals, the normal process of cell division consists of DNA replication (S 
phase) and mitosis (M phase), where a cell divides into two daughter cells. After 
mitosis, the diploid cell (2N) enters G1 stage, proceeded to S phase in which the 
DNA replication occurs. During this time, the diploid cell becomes tetraploid (4N). 
There is a gap between S and M phases known as G2. The cells in G1 stage will enter 
a quiescent state called G0 if there is absence of appropriate growth factor, without 
entering the rest of cell-cycle division. 
 
pRB is a tumor suppressor protein that controls the G1/S cell-cycle checkpoint. pRB 
protein is found in the nuclei of all cell types and at all stages of the cell cycle. 
Several studies found that phosphorylation of pRB occur at G0 phase of the cell cycle 
(Chen et al., 1989; DeCaprio et al., 1992; Ludlow et al., 1990). Nonphosphorylated 
form of pRB has the binding ability to transcription factor E2F and forms pRB/E2F 
complex. This complex blocks the transition of normal cells from G1 into S stage in 
the cycle (Ludlow et al., 1990). Growth factors stimulate the cells to enter G1 and 
approaches S phase. Throughout the G1 phase, pRB is phosphorylated by the 
CDK4/cyclin D1 complex. Phosphorylated pRB releases its bound regulatory 
protein. When E2F and other regulators are released by pRB, they can induce the 
transition of cells from G1 to S phase. After cells passed by S, G2 and M phases, pRB 
return back to its nonphosphorylated state and binds to regulatory protein such as 
E2F, and keeps them apart, until they required for the next cell cycle. The presence 
of pRB protein prevents the transition into S phase in normal quiescent cells. In 
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many cancer cells including retinoblastoma, both copies of RB1 can be defective, 
inactive, or absent that cause unregulated cell cycle (Klug, 2010). 
 
pRB can bind with several viral oncoproteins such as adenovirus E1A protein, 
polyoma large T antigens, and human papillomavirus (HPV) E7. However, these 
viruses may use a similar mechanism in transformation, and this may cause 
inactivation of retinoblastoma. The inactivation of pRB may be due to the binding 
with these viral oncoproteins. The binding may disrupts the pRB/E2F complexes and 
leads to the activation of E2F-responsive genes that cause progression of the cell-
cycle from G1 to S phase (Sellers and Kaelin, 1997).  
 
1.5 Spectrum of mutations in RB1 
 
Mutation is defined as changes in the sequence of genomic DNA. It may comprise a 
single base-pair substitution, deletion or insertion of one or more base pairs to major 
alteration in the structure of a chromosome. Mutations may occur within regions of a 
gene that code for protein or within noncoding regions of a gene, such as introns and 
regulatory sequences. Mutations may or may not bring changes in phenotype. The 
level of a mutation can change the characteristics of an organism depends on where 
the mutation occurs, and the degree to which mutation alters the function of the gene 
product.  
 
The severity of mutations depends on the site of mutation; in somatic cells or germ 
cells. Germ cell mutations are heritable and become the basis for the transmission of 
genetic diversity and evolution, as well as genetic diseases. Somatic cell mutations 
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are usually non-transmittable to the next generation, but may lead to altered cellular 
functions of tumors (Klug et al., 2010). 
 
Geneticists usually classify the gene mutations in terms of nucleotide changes. A 
change of one base pair to another base pair in DNA molecule is known as point 
mutation, or base substitution. A change of one nucleotide of a triplet within a 
protein-coding portion of a gene may result in a creation of a new triplet which codes 
for different amino acid in protein product; known as a missense mutation. However, 
if the triplet amino acid changed into a stop codon, the translation of the protein will 
terminate, and this is known as nonsense mutation. If the point mutation alters a 
codon but does not result in a change in the amino acid at that position in the protein 
(due to degeneracy of genetic code), it can be considered as a silent mutation. 
 
Another type of change is the insertion or deletion of one or more nucleotides at any 
point of the gene. The loss or addition of a single nucleotide causes the triplet codon 
to be changed. These are called frameshift mutations because the frame of triplet 
reading during translation has altered. A frameshift mutation will occur when any 
number of bases are added or deleted, except the triplet, which would develop the 
initial frame for reading. It is possible that one of the many altered triplets will be 
UAA, UAG or UGA, the translation termination codons. When one of these triplets 
is encountered during translation, the synthesis of polypeptide will be terminated at 
that point (Klug et al., 2010). 
 
Inactivation of RB1 is associated with retinoblastoma. Loss of function of RB1 is also 
found in other tumor types such as lung carcinoma, non-small cell lung cancer and 
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esophageal cancer, based on loss of heterozygosity (LOH) and absence of RB1 
expression in these tumors (Xing et al., 1999; Tamura et al., 1997). Low expression 
of RB1 was also found with loss of function mutations or epigenetic phenomenon, 
where hypermethylations occur within 5’ promoter region (Lohmann, 1999). 
 
RB1 mutations are found scattered along the whole sequence of genomic DNA and 
accumulated at discrete region with high recurrence mutations. Majority of the 
mutations affect coding sequence with higher number at globular domain A and B 
that interrupt binding function with RB1-associated protein (Lohmann, 1999; 
Valverde et al., 2005). 
 
1.5.1 Chromosomal aberration 
 
Based on karyotyping, previous studies showed that less than 10% of patients with 
RB had constitutional chromosome 13q abnormalities, and majority with deletions 
(Bunin et al., 1989a). Cytogenetic or chromosome aberration is disruption of 
chromosomal content in a cell producing either abnormal number or structure of 
chromosomes. Other karyotpye abnormalities including mosaic and nonmosaic 
deletions, de novo translocation, deletion and insertion involving 13q14 in peripheral 
blood lymphocytes of 7.5% bilateral RB and 4.9% among unilateral RB (Bunin et 
al., 1989b). High frequency of chromosomal aberration was found in Indian RB 
patients, where abnormal karyotypes were seen within all tumor samples. 
Abnormalities were seen in all chromosomes except sex chromosome with half 
(50%) of abnormalities seen in chromosome 13. Most frequent changes are structural 
aberration such as 13q14 deletions (Harini et al., 2001), translocations and 
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aneusomies. The study had suggested that locus of 13q14 as fragile site that might 
play role in retinoblastoma carcinogenesis (Amare Kadam et al., 2004). 
 
1.5.2 Small-length mutation 
 
A review by Lohmann (1999) found that most of the mutations in RB1 gene were 
dominated by small length mutation such as single base substitution, small insertion 
and deletion (Lohmann, 1999). The most common single base substitution is 
nonsense mutations, with small frequency of missense mutations (Lohmann, 1999; 
Brichard et al., 2006; Abouzeid et al., 2007). A C to T transition involving CGA-
arginine codon is the most common nonsense mutations (Lohmann et al., 1996). It is 
generally assumed that hypermutability at CGA codon are dependent on methylation 
status at CpG island and deamination of 5-methyl cytosine to thymidine (Mancini et 
al., 1997). In addition to nonsense mutations, frameshift and splicing mutations are 
also found to scatter along the genomic sequence of RB1 (Valverde et al., 2005). 
Frameshift and splicing mutation exert deleterious effect due to alteration of final 
product of pRB protein. (Tsai et al., 2004) demonstrated that RB1 frameshift 
mutation demonstrated causes earlier stop codon within exon 19 and producing 
truncated pRB protein. RB1 frameshift distributed unequally within exonic and 
intronic region of RB1 (Valverde et al., 2005; Braggio et al., 2004). In contrast, 
splicing mutation commonly occur in adjacent intronic within intron-exon junction 
or splicing site of RB1 (Valverde et al., 2005). There is uneven distribution of small 
mutation at splice site of open reading frame of RB1 in both acceptor and donor sites. 
Most frequent splice site mutation affected intron-exon 19 and 24 (Lohmann, 1999). 
Researchers found that splice site mutation leads to exon skipping and producing 
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defective protein with lack of amino acid sequence (Nichols et al., 2005; Valverde et 
al., 2005). 
 
1.5.3 Hypermethylation of CpG Island 
 
CpG island is a short stretch of DNA with higher frequency of CG sequence 
compared to other regions. CpG islands are usually located around the promoters of 
housekeeping genes or other genes frequently expressed in a cell.  CG is normally 
not methylated at these locations.  By contrast, the CG sequences in inactive genes 
are usually methylated to suppress their expression. Methylation of cytosine (C) 
nucleotide converts the cytosine to 5-methylcytosine. Therefore, the transcription 
machinery fails to recognize 5-methylcytosine, halt the transcription and turn off the 
gene. 
 
Hypermethylation at CpG island of 5’-promoter region was found to decrease the 
expression of RB1 (Kishi et al., 2005). Hypermethylation of RB1 in tumor tissues is 
believed to cause allelic inactivation of the gene (Sakai et al., 1991; Ohtani-Fujita et 
al., 1993; Ohtani-Fujita et al., 1997). Specific hypermethylation at promoter region 
of RB1 reduced expression of the gene. Hypermethylation also was found at 5’-end 
of the gene without any chromosomal aberrations. This provides evidence to support 
the hypothesis that CpG methylation of the human tumor-suppressor gene causes the 
inactivation of the gene and lead to tumor formation (Ohtani-Fujita et al., 1997). In 
addition, hypermethylation at CpG island have been suggested to interrupt the 
binding site of transcription factor (ATF)-like factor and retinoblastoma binding 
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factor 1 (RBF-1) that are important for activities of promoter (Ohtani-Fujita et al., 
1993).  
 
1.5.4 Single nucleotide polymorphism 
 
Single nucleotide polymorphism (SNP) is genomic DNA variation that occurs when 
single nucleotides A, T, C or G differs within population of organism. SNPs are the 
most common type of genetic variation among people. A variation can be considered 
as SNP if it presents in at least 1% within population in a time (Carlson, 2008). SNPs 
normally occur throughout individual’s DNA. SNPs can act as biological markers 
that can help scientists to locate genes that are associated with disease.  SNPs can be 
nucleotide substitution, insertion or deletion. It may present in coding sequence, 
noncoding sequence, and promoter region. SNPs within coding sequence that change 
amino acid may cause deleterious effect (Lohmann, 1999). The importance of SNPs 
are spread in a broad range of cases since it can show up to 80% differences between 
two individual (Carlson, 2008). Certain SNPs may help to predict individual’s 
response to certain drugs, susceptibility to environmental factors such as toxins, and 
risk of developing particular diseases (Collins et al., 1998). SNPs can also be used to 
track the inheritance of disease genes within families (Carlson, 2008). Although 
99.9% of genetic profile in all human are similar but variation in 0.1% of the human 
genome have high impact to each individual in term of response to different diseases, 
environment or drug treatment (Orphanides and Kimber, 2003). Almost 90% of 
variation in human genetics is SNP (Collins et al., 1998). Therefore, SNPs are 
valuable for medical diagnostic development especially for pharmacogenetics study. 
Common SNPs in RB1 such as IVS3+45C>T (rs520342), IVS4+22G>T (rs198617) 
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and IVS4-77G>A (rs198616) were found to significantly associate with various 
diseases such as ovarian cancer, breast cancer, bladder cancer and retinoblastoma 
(Song et al., 2006; Lesueur et al., 2006; Majewski et al., 2008; Kim et al., 2006; 
Lohmann, 1999). Most of reported SNPs in RB1 were found in intronic region 
(Leone et al., 2003; Lohmann, 1999; Schubert and Hansen, 1996). 
 
1.6 Mutation detection technique 
 
Various techniques for DNA mutational analysis are available (Cotton, 1997). The 
example of mutation detection technique is denaturing gradient gel electrophoresis 
(DGGE). This method was developed based on the principles that different 
sequences of double-stranded DNA (dsDNA) melt under different condition. 
However, this method was formatted for manual use only, technically challenging, 
limited by the sensitivity of detection as well as time consuming (Xiao and Oefner, 
2001; Vidal-Puig and Moller, 1994; Couch and Weber, 1996). 
 
Another method is single strand conformational polymorphism (SSCP). This method 
used the principle of difference conformation of secondary structure from single 
stranded (ss) DNA under certain condition. The secondary structure of single strand 
DNA is corresponding to the base composition in the DNA sequence. Any nucleotide 
changes, even one nucleotide may caused the differences of the structure, thus 
interrupt the electrophoretic mobility under non-denaturing condition. Under optimal 
condition, with sequence region <200bp, SSCP can detect up to 80% to 90% of all 
mutations in gene (Sheffield et al., 1993). However, SSCP method cannot be 
successfully applied on long stretch of DNA. 
